Press release
The Life Raft Group, a Non-profit Supporting Patients with GIST Cancer, Announces Members of the 2021 Medical Advisory Board
Wayne, NJ, March 17, 2021- The Life Raft Group (LRG), a patient advocacy organization supporting patients with Gastrointestinal Stromal Tumor (GIST), a rare cancer, announced today the members of their 2021 Medical Advisory Board.Comprised of experts from leading academic and medical institutions around the world, the goal of the MAB is to share scientific and research expertise to provide strategic direction on LRG initiatives to ensure the survival and well-being of GIST patients.
The recognized experts and key opinion leaders are:
Suzanne George, MD is the Clinical Research Director of the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. She also serves as senior physician to the affiliate staff in the Division of Adult Oncology at Brigham and Women’s Hospital.
Michael Heinrich, MD is a medical oncologist and Professor of Medicine and Cell/Developmental Biology at Oregon Health and Science University (OHSU School of Medicine).
Sameer Rastogi, MD is a faculty member in the Department of Medical Oncology at All India institute of Medical Sciences (AIIMS), New Delhi, a leading tertiary care center in North India.
Peter Reichardt, MD is Assistant Professor and Head of the Department of Oncology and Palliative Care at the Helios Klinikum Berlin-Buch in Berlin, Germany, and is Director of the Cancer Center Berlin-Buch and the Sarcoma Center Berlin-Brandenburg.
Gary K. Schwartz, MD is a board-certified medical oncologist and internist and chief of Columbia University Medical Center's Division of Hematology and Oncology.
Jason Sicklick, MD, FACS is an NIH and FDA R01 funded investigator, Professor of Surgery, Executive Vice Chair of Research in the Department of Surgery, and Co-Leader of the Sarcoma Disease Team at the UC San Diego Moores Cancer Center.
Jonathan Trent., MD, PhD the Associate Director for Clinical Research, the Director of the Bone and Soft-tissue Sarcoma Group and Medical Director of the Precision Medicine Initiative at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
To quote Norman Scherzer, Executive Director of the Life Raft Group, ““The Life Raft Group is excited to collaborate with our Medical Advisory Board to address the vital issues affecting the survival and well-being of GIST patients.”
Contact:
Mary Garland, Director of Communications
mgarland@liferaftgroup.org
155 US Highway 46
Suite 202
Wayne, NJ 07470
(973) 837-9092, ext. 108
About the Life Raft Group
The Life Raft Group is a non-profit with a simple focus: to cure a form of cancer – GIST (gastrointestinal stromal tumors) – and to help those living with it until then. The mission is to ensure the survival of GIST patients through a comprehensive approach connecting individual patients’ needs, the worldwide community of GIST advocates and the global health and research environment. This is achieved by focusing on three key areas: Patient Support & Education, Advocacy and Research.
To learn more, visit www.liferaftgroup.org
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The Life Raft Group, a Non-profit Supporting Patients with GIST Cancer, Announces Members of the 2021 Medical Advisory Board here
News-ID: 2257171 • Views: …
More Releases from The Life Raft Group

The Life Raft Group Announces New Board Members
FOR IMMEDIATE RELEASE
The Life Raft Group Announces New Board Members
Expanded Board will aid in the development of new initiatives
Wayne, NJ, April 26, 2021 The Life Raft Group (LRG), a patient advocacy organization specializing in GIST (Gastrointestinal Stromal Tumor) cancer, welcomed two new members to its Board of Directors, Kay Stolzer and Dr. Monica (mOe) Anderson.
Comprised of individuals who are passionately invested in finding a cure for GIST, and to supporting…
More Releases for GIST
Benchmark Gensuite & GIST Impact Announce Partnership To Bring Unprecedented Cla …
Benchmark Gensuite, a leading provider of cloud-based Environmental, Health, Safety (EHS), and Sustainability software solutions, and GIST Impact, a market-leading impact data and analytics provider, today announced a strategic partnership to deliver comprehensive sustainability management and reporting capabilities to global organizations.
This collaboration brings together Benchmark Gensuite's robust digital platform for EHS and sustainability management with GIST Impact's advanced impact data and analytics expertise. The partnership will empower companies with enhanced…
Gastrointestinal Stromal Tumors (GIST) Clinical Trials 2024: FDA Approval, Medic …
(Albany, USA) DelveInsight's, "Gastrointestinal Stromal Tumors Pipeline Insight 2024" report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors (GIST) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
Global Market Overview 2024: Gastrointestinal Stromal Tumor (GIST) Treatment Tre …
"The Business Research Company recently released a comprehensive report on the Global Gastrointestinal Stromal Tumor Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The gastrointestinal stromal tumor…
Gastrointestinal Stromal Tumor (GIST) Drug Market to see Rapid Growth by 2028
The Gastrointestinal Stromal Tumor (GIST) Drug Market size is expected to grow at an annual average of CAGR 5% during the forecast period (2022-2028). Gastrointestinal stromal tumor (GIST) is recognized as one of the most common mesenchymal tumors worldwide. According to the World Health Organization (WHO), the estimated incidence of gastrointestinal stromal tumors is 14.5 per million people and is prevalent in 129 out of 1 million samples in the…
Chatbot Builder Software Market to See Huge Growth by 2027 | Gist, MobileMonkey, …
Global Chatbot Builder Software Market Report 2021 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Chatbot Builder Software Market. Some of the key players profiled in the study are Tars, ChatBot, Gist, MobileMonkey,…
YabaLeftOnline NG Presenting the Latest Naija Gist and Nigeria Entertainment New …
YabaLeftOnline NG is a leading online platform in Nigeria that offers a wide variety of news from across the country. The platform displays Naija gist, as well as viral news in Nigeria. On YabaLeftOnline NG, its readers can check out the popular Nigerian music videos, music world’s news, and comedy skits. Whether it is Banky W’s campaign posters being destroyed in Lagos or the latest about BBNaija star Anto, the…